Comparing multiple myeloma treatment plans
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study looks at two different drug combinations for people with multiple myeloma who are eligible for a stem cell transplant. It aims to find which treatment works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have multiple myeloma
- You are eligible for a stem cell transplant based on your health and ability to function
- You received a treatment plan that included a combination of drugs
- Your medical records are complete
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at two different drug combinations given before a second stem cell transplant for multiple myeloma that has come back after first treatment. It aims to see if adding two extra drugs (bortezomib and bendamustine) to the standard drug (melphalan) works better than using the standard drug alone.
This Phase 3 trial tests the best combination of medicines for newly diagnosed multiple myeloma patients who are headed to an autologous stem cell transplant (ASCT). It compares extended VRD plus versus Isa-VRD versus Isa-V-Iberdomide to see which approach works best and is tolerable.
This trial compares two different combinations of medications for people with newly diagnosed multiple myeloma who are not planning to have a stem cell transplant. It looks at whether adding a targeted antibody drug is as effective as the standard approach.
This study tests a combination of four cancer-fighting drugs (isatuximab, iberdomide, bortezomib, and dexamethasone) followed by a stem cell transplant for people newly diagnosed with multiple myeloma. The goal is to see if this approach can help patients live longer and control their disease better.
This study compares different combinations of medicines for people newly diagnosed with multiple myeloma who cannot safely get a stem cell transplant. It aims to find which drug plan works best and is tolerable for people with “frail” or “intermediate fit” health.
This trial tests whether a new drug called elranatamab combined with lenalidomide works better than the standard daratumumab/lenalidomide combination as maintenance therapy after a stem cell transplant for newly diagnosed myeloma.
Hear when a new Survivorship trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.